Uno studio recente sta dando nuova speranza a coloro che soffrono di depressione difficile da trattare.
According to researchers, psilocybin, a compound found in psychedelic mushrooms, may be useful in treatment-resistant depression. The preliminary study was published in the journal Rapporti scientifici and has some all ears over its findings.
Researchers began by analyzing functional magnetic resonance imaging (fMRI) data of 19 participants with a diagnosis of treatment-resistant major depression; they did not organize a control group with placebos. Before and after receiving psilocybin, 16 of the 19 participants had their cerebral blood flow (CBF) and blood oxygen-level dependent (BOLD) resting-state functional connectivity (RSFC) examined by researchers.
In the findings, researchers say all 19 participants exhibited a rapid decrease in depressive symptoms in the first week following treatment with psilocybin. At five weeks in, almost half of all participants, or 47%, continued to show therapeutic conditions.
La psilocibina ha colpito due aree del cervello: la rete in modalità predefinita e l'amigdala, causando ai partecipanti un "reset" nel cervello, secondo lo studio.
"Le analisi dell'intero cervello hanno rivelato diminuzioni post-trattamento nella CBF nella corteccia temporale, inclusa l'amigdala. Diminuzione dell'amigdala CBF correlata a sintomi depressivi ridotti ", ha rilevato lo studio.
While the results suggest that psilocybin, a serotonin agonist, can have significant benefits on the brain, it shouldn’t be utilized to self-medicate, researchers warned; as its effects on the brain are still poorly understood.